Medical Oncology

Uzm. Dr. Duygu Özaşkın

Doctor and researcher Afyonkarahisar Devlet Hastanesi Afyonkarahisar
Carcinoma, Non-Small-Cell LungLung NeoplasmsBreast Neoplasms
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Carcinoma, Non-Small-Cell Lung 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Lung Neoplasms 3 publications
  • Breast Neoplasms 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionAfyonkarahisar Devlet Hastanesisaglik.gov.trFrom source
  • Area of workCarcinoma, Non-Small-Cell LungExtracted from 3 publications · Model version —From source
  • Publications14 publicationsOpenAlex, Europe PMC, ORCIDFrom source
  • ORCID0009-0004-6376-8399ORCIDFrom source
  • Last synchronised5 November 2026 07:10https://afyonkarahisardh.saglik.gov.tr/TR-1328495/tibbi-onkoloji-doktorlarimiz.html#duygu-ozaskinsaglik.gov.tr

Scientific work

Publications on Carcinoma, Non-Small-Cell Lung

14 publications

  1. Palliative Care Awareness Among Caregivers of Cancer Patients in Turkey: A Cross-Sectional Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33080458 PMID 42645362 Open-access full textSource: OpenAlex

  2. ARE mGPS, SIS, AND LCS SIGNIFICANT IN PREDICTING FIRST-LINE PALLIATIVE CHEMOTHERAPY RESPONSE AND PROGNOSIS IN PATIENTS WITH METASTATIC GASTRIC CANCER?

    Zenodo (CERN European Organization for Nuclear Research), 2026

    DOI 10.5281/zenodo.18936420 Open-access full textSource: OpenAlex

  3. Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

    Scientific reports, 2026

    DOI 10.1038/s41598-026-48955-9 PMID 41981174 Open-access full textSource: Europe PMC

  4. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-026-04228-5 PMID 41670816 Source: Europe PMC

  5. Aprepitant and Fosaprepitant for Preventing Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy—A Real-World Study

    Current Oncology, 2026

    DOI 10.3390/curroncol33070381 PMID 42505183 Open-access full textSource: ORCID

  6. The Effect of HER3 Expression on Prognosis in EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62030538 PMID 41901620 1 citation (Europe PMC) Open-access full textSource: ORCID

  7. Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

    Discover Oncology, 2025

    DOI 10.1007/s12672-025-03886-1 PMID 41249604 Open-access full textSource: OpenAlex

  8. Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first‐line therapy in advanced nonuterine leiomyosarcoma: A multicenter real‐world study

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70212 PMID 41147691 Source: OpenAlex

  9. HEREDITARY COLORECTAL CANCER SYNDROMES

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-770-4_p17 Source: OpenAlex

  10. Metastatik Meme Kanserinde Birinci Basamak Tedavi Sonuçlarının Değerlendirilmesi

    Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi, 2025

    DOI 10.17517/ksutfd.1341433 Open-access full textSource: ORCID

View all 14 publications